The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia

Clinical Neuropharmacology

Volumn 32, Issue 4, 2009, Pages 224-226

  Kim, Sung Wan ^a   Shin, Il Seon ^a   Kim, Jae Min ^a   Youn, Tak ^a   Yang, Su Jin ^a   Hwang, Michael Y ^a   Yoon, Jin Sang ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Chonnam National University   (South Korea)

Author keywords

Amisulpride; Aripiprazole; Obsessive compulsive symptoms; Risperidone; Schizophrenia; Ziprasidone

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; RISPERIDONE; SEROTONIN 2A RECEPTOR; ZIPRASIDONE;

ADULT; AGITATION; AMENORRHEA; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISTRESS SYNDROME; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PARANOID SCHIZOPHRENIA; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOSIS; RUMINATION; SEDATION; SEXUAL BEHAVIOR; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; QUINOLONES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN, 5-HT2; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68949183337     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318184fafd     Document Type: Article

References (19)

1. Alevizos B, Lykouras L, Zervas IM, et al. Risperidone-induced obsessive-compulsive symptoms: a series of six cases. J Clin Psychopharmacol 2002;22:461-467.
2. Lykouras L, Alevizos B, Michalopoulou P, et al. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 2003 ;27: 333-346.
3. Desarkar P, Das A, Nizamie SH. Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. J Clin Psychopharmacol 2007;27:305-306.
4. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006;11:622-632. (Pubitemid 43989810)
5. Ramasubbu R, Ravindron A, Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry 2000;33:236-238.
6. Khullar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 2001;26:55-59.
7. Kim SW, Shin IS, Kim JM, et al. Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. J Clin Psychopharmacol 2008;28:349-352.
8. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68(suppl 1):20-27.
9. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1: BGoldilocks[ actions at dopamine receptors. J Clin Psychiatry 2001;62:841-842.
10. Schmidt AW, Lebel LA, Howard HR Jr, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201.
11. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999;20:491-505.
12. Dunner DL, Amsterdam JD, Shelton RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007;68: 1071-1077.
13. Kaptsan A, Dwolatzky T, Lerner V Ziprasidone-associated depressive state in schizophrenic patients. Clin Neuropharmacol 2007;30:357-361.
14. Iglesias Garcia C, Santamarina Montila S, Alonso Villa MJ. Ziprasidone as coadjuvant treatment in resistant obsessive-compulsive disorder treatment. Actas Esp Psiquiatr 2006;34:277-279.
15. Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am 2000;23: 563-586.
16. Kim CH, Cheon KA, Koo MS, et al. Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology 2007;55:156-162.
17. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124: 57-73.
18. Li X, May RS, Tolbert LC, et al. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 2005;66:736-743.
19. Hwang MY, Bermanzohn PC, Opler LA. Obsessive-compulsive symptoms in patients with schizophrenia. In: Hwang MY, Bermanzohn PC, eds. Schizophrenia and Comorbid Conditions. Washington, DC: American Psychiatry Press; 2001:57-78.